apl. Prof. Dr. Markus Heppt

Medizinische Fakultät Department of Dermatology

Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study. (2023) Tomsitz D, Ruf T, Heppt M, Staeger R, Ramelyte E, Dummer R, Garzarolli M, et al. Journal article Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial (2023) Koch E, Petzold A, Wessely A, Dippel E, Eckstein M, Gesierich A, Gutzmer R, et al. Journal article Cutaneous squamous cell carcinoma: state of the art, perspectives and unmet needs (2023) Heppt M, Leiter U Journal article One Website to Gather them All: Usability Testing of the New German SKin Cancer INFOrmation (SKINFO) Website-A Mixed-methods Approach (2022) Steeb T, Bruetting J, Reinhardt L, Hoffmann J, Weiler N, Heppt M, Erdmann M, et al. Journal article eImmunonkologie: Development and Launch of a Virtual Education Platform for the Immunotherapy of Cutaneous Neoplasms (2022) Kaufmann M, Steeb T, Wessely A, Meyerolbersleben M, French LEE, Berking C, Heppt M Journal article Real-world outcomes using PD-1 antibodies and BRAF plus MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland (2022) Schumann K, Mauch C, Klespe KC, Loquai C, Nikfarjam U, Schlaak M, Akcetin L, et al. Journal article Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre study (2022) Thiem A, Mashhadiakbar P, Cussigh C, Hassel JC, Grimmelmann I, Gutzmer R, Schlaak M, et al. Journal article CHALLENGES OF NETWORK META-ANALYSIS FOR SAFETY OUTCOMES: THE ANALYSIS OF TIRBANIBULIN AGAINST COMMON TREATMENTS IN EUROPE FOR ACTINIC KERATOSIS (2022) Heppt M, Dykukha I, Chapman-Rounds M, Graziadio S, Edwards M Conference contribution ASSESSING SIMILARITY OF STUDIES FOR NETWORK META-ANALYSIS: THE USE OF FEASIBILITY ASSESSMENT AND SENSITIVITY ANALYSES TO ESTIMATE THE EFFICACY OF TIRBANIBULIN, A NEW DRUG FOR ACTINIC KERATOSIS (2022) Heppt M, Dykukha , Chapman-Rounds M, Graziadio S, Edwards M Conference contribution Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry (2022) Haist M, Stege H, Lang BM, Tsochataridou A, Salzmann M, Mohr P, Schadendorf D, et al. Journal article